ClinicalTrials.gg
Sign In

Hereditary Breast and Ovarian Cancer Syndrome clinical trials

The registry lists 62 studies for Hereditary Breast and Ovarian Cancer Syndrome across more than 10 countries. 13 are recruiting or about to start. 40 of them are mainly about Hereditary Breast and Ovarian Cancer Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Get an email when these change. Save the Hereditary Breast and Ovarian Cancer Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Status

Completed
31
Recruiting
9
Active, not recruiting
7
Status unknown
6
Terminated
4
Not yet recruiting
3

Phase

Phase 2
7
Phase 3
3
Phase 1
2
Early Phase 1
1
Phase 4
1

Where

United States
35
France
7
Israel
3
China
3
Sweden
2
Canada
2

Who runs them

Georgetown University (6) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · Gynecologic Oncology Group (2) · Abramson Cancer Center at Penn Medicine (2) · Technical University of Munich (2) · Sheba Medical Center (2) · University Health Network, Toronto (2)

What is being tested here

Drugs under test in Hereditary Breast and Ovarian Cancer Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Veliparib002
Letrozole011
Zoledronic Acid001
Carboplatin001
Docetaxel001
Arzoxifene hydrochloride001
Tamoxifen001
Prexasertib001

Coming up

0phase 3 studies under way
5studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5

Who these studies take

Of the 9 Hereditary Breast and Ovarian Cancer Syndrome studies recruiting now, 6 (67%) set no upper age limit and 1 (11%) stop at 75 or younger. 3 (33%) take children under 18. 4 (44%) are for women only and 0 (0%) for men only; 3 (33%) take healthy volunteers.

Recruiting studies that take each age, of 9
AgeWomenMen
103 (33%)3 (33%)
189 (100%)5 (56%)
309 (100%)5 (56%)
409 (100%)5 (56%)
509 (100%)5 (56%)
659 (100%)5 (56%)
758 (89%)5 (56%)
857 (78%)5 (56%)

Across all 62 studies, recruiting or not: 18% stop at 75 or younger and 8% at 65; 16% take children; 60% are for women only and 0% for men only; 34% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hereditary Breast and Ovarian Cancer Syndrome studies take

Of 22 interventional studies with no phase under Hereditary Breast and Ovarian Cancer Syndrome, half reached primary completion within 55 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase55 mo31–… · 22 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 16, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 62. Browse all 62 → or search them.